Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial
Titel:
Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial
Auteur:
Wang, Michael L Jain, Preetesh Zhao, Shuangtao Lee, Hun Ju Nastoupil, Loretta Fayad, Luis Ok, Chi Young Kanagal-Shamanna, Rashmi Hill, Holly A Yao, Yixin Hagemeister, Fredrick B Westin, Jason R Fowler, Nathan Samaniego, Felipe Steiner, Raphael Nair, Ranjit Iyer, Swaminathan P Navsaria, Lucy Badillo, Maria Feng, Lei Xuelin, Huang Nogueras Gonzalez, Graciela M Xu, Guofan Wagner-Bartak, Nicolaus Thirumurthi, Selvi Santos, David Tang, Guilin Lin, Pei Wang, Sa A Jorgensen, Jeff Yin, C Cameron Li, Shaoying Patel, Keyur P Vega, Francisco Medeiros, L Jeffery Flowers, Christopher R Wang, Linghua